bevacizumab
roche
['cairo5']
dr. punt w/ cairo5: folfoxiri-bev vs folfox/folfiri-bev in initially unresectable clm and r colon and/or ras/braf mutated primary tumor. median pfs 10.6 vs 9.0 months (hr 0.77 p=0.038). os data not mature. r0/1 resection +/- ablation rate 51 vs 37% #asco22 
Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine.